# Emma Guttman‐Yassky

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/emma-guttman-yassky/

## Facts

| Field | Value |
| --- | --- |
| Citations | 47,254 |
| Field | Dermatology and Skin Diseases |
| h-index | 116 |
| i10-index | 376 |
| Last Known Institution | Mount Sinai Hospital |
| OpenAlex ID | https://openalex.org/A5024365532 |
| ORCID iD | https://orcid.org/0000-0002-9363-324X |
| Works | 764 |

## Researcher papers

Showing 12 of 15.

- [Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis](https://scholariq.org/papers/two-phase-3-trials-of-dupilumab-versus-placebo-in-atopic-dermatitis/)
- [Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis](https://scholariq.org/papers/dupilumab-treatment-in-adults-with-moderate-to-severe-atopic-dermatitis/)
- [Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis](https://scholariq.org/papers/dupilumab-progressively-improves-systemic-and-cutaneous-abnormalities-in/)
- [Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*](https://scholariq.org/papers/tralokinumab-for-moderate-to-severe-atopic-dermatitis-results-from-two-52-week/)
- [Cellular and molecular immunologic mechanisms in patients with atopic dermatitis](https://scholariq.org/papers/cellular-and-molecular-immunologic-mechanisms-in-patients-with-atopic-dermatitis/)
- [Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials](https://scholariq.org/papers/once-daily-upadacitinib-versus-placebo-in-adolescents-and-adults-with-moderate/)
- [Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis](https://scholariq.org/papers/efficacy-and-safety-of-dupilumab-in-adolescents-with-uncontrolled-moderate-to/)
- [Conjunctivitis in dupilumab clinical trials](https://scholariq.org/papers/conjunctivitis-in-dupilumab-clinical-trials/)
- [Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase<scp>III</scp>trials](https://scholariq.org/papers/baricitinib-in-patients-with-moderate-to-severe-atopic-dermatitis-and-inadequate/)
- [Increasing Comorbidities Suggest that Atopic Dermatitis Is a Systemic Disorder](https://scholariq.org/papers/increasing-comorbidities-suggest-that-atopic-dermatitis-is-a-systemic-disorder/)
- [Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis](https://scholariq.org/papers/two-phase-3-trials-of-lebrikizumab-for-moderate-to-severe-atopic-dermatitis/)
- [Nomenclature of allergic diseases and hypersensitivity reactions: Adapted to modern needs: An <scp>EAACI</scp> position paper](https://scholariq.org/papers/nomenclature-of-allergic-diseases-and-hypersensitivity-reactions-adapted-to/)

## Researcher topics

- [Dermatology and Skin Diseases](https://scholariq.org/topics/dermatology-and-skin-diseases/)
- [Asthma and respiratory diseases](https://scholariq.org/topics/asthma-and-respiratory-diseases/)
- [Psoriasis: Treatment and Pathogenesis](https://scholariq.org/topics/psoriasis-treatment-and-pathogenesis/)
- [Allergic Rhinitis and Sensitization](https://scholariq.org/topics/allergic-rhinitis-and-sensitization/)
- [Urticaria and Related Conditions](https://scholariq.org/topics/urticaria-and-related-conditions-2/)

## Researcher university

- [Mount Sinai Hospital](https://scholariq.org/institutions/mount-sinai-hospital-4/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.